BioSpace News Archive

MaxCyte, Inc. The company today announces that its Board of Directors has appointed Richard Douglas, PhD, as Chair of the Board.

OS Therapies, a research and clinical-stage biopharmaceutical company whose lead program uses OST-HER2 is being developed for therapies to treat and cure Osteosarcoma, announced the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation for OST-HER2 for the treatment of Osteosarcoma.

The Carling Adrenal Center, a worldwide destination for the surgical treatment of adrenal tumors, becomes the first center to offer adrenal vein sampling and curative surgery in one visit.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated clinical data from a Phase 1 study of tidutamab, an SSTR2 x CD3 bispecific antibody, in patients with neuroendocrine tumors (NETs).

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the appointment of Cary J. Claiborne to the Board of Directors, increasing the number of board members to seven.

OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions, today announced the OVMed® OH0FA image sensor and OAH0428 bridge chip for endoscopes and catheters.

Evotec SE will announce its financial results for the first nine months 2021 on Thursday, 11 November 2021.

TransThera Sciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its phase II stage product TT-00420 for the treatment of patients with Cholangiocarcinoma (CCA) who have no standard treatment options.

United Spinal Association is pleased to announce that it will host a virtual gala and community event on Wednesday, November 10 at 6 pm EST , to celebrate 75 years of progress in building an inclusive world for people living with spinal cord injuries and disorders (SCI/D).

Alpha Tau Medical Ltd. announced today that it has enrolled its first patient in the combination study of Alpha DaRT and pembrolizumab (Keytruda ® ) at Hadassah Medical Center in Jerusalem, Israel .